Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)


Monday 28 September, 2020

BioPharma Credit PLC


RNS Number : 2023A
BioPharma Credit PLC
28 September 2020



BioPharma Credit plc

(the "Company")




BioPharma Credit PLC (the "Company"), is pleased to announce that, together with Sarepta Therapeutics, Inc ("Sarepta"), and BioPharma Credit Investments V (Master) LP ("BioPharma-V") it has entered into a first amendment to the loan agreement dated 13 December 2019.  


Under the original terms of the loan agreement, the Company agreed to invest up to US$350 million (US$175 million in the first tranche ("Tranche A") and up to an additional US$175 million by 31 December 2020 ("Tranche B")) and BioPharma-V agreed to invest up to US$150 million in parallel with the Company acting as collateral agent. The loan had an original maturity date of December 2023 and paid interest at 8.50 per cent. per annum along with a one-time additional consideration of 1.75 per cent. of the total loan amount payable upon funding and an additional 2.00 per cent. payable upon the repayment of the loan. 


The amendment increases the aggregate principal amount of Tranche B from US$250 million to US$300 million. The Company's investment in Tranche B will remain unchanged at US$175 million while BioPharma-V will increase its investment by US$50 million. The Company's US$350 million aggregate investment in Sarepta will represent 25% of the Company's portfolio. Sarepta has agreed to draw Tranche B in full, on or prior to 2 November 2020, as long as the conditions to funding the Tranche B are satisfied or waived. In addition, the Amendment extends the maturity date for the Tranche B Loan to 31 December 2024 and increases the funding fee payable to each Lender providing a portion of the Tranche B Loan on the date the Tranche B Loan is funded by 1.20 per cent. to 2.95 per cent.



BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500



+44 (0)20 7466 5000 / [email protected]

David Rydell

Mark Court

Jamie Hooper

Henry Wilson


Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27   March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.


LEI: 213800AV55PYXAS7SY24


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t